Gene therapy platform with one approval, FDA-aligned Danon pivotal underway, and a PKP2 design update as the next make-or-break gate

Rocket Pharmaceuticals is a clinical-stage gene therapy company developing treatments for rare genetic diseases, with one approved gene therapy for a severe immune disorder and a pivotal trial underway for a fatal heart condition not yet approved by the FDA.

Rocket holds an accelerated approval for KRESLADI in severe LAD-I and now has FDA-confirmed pivotal parameters for RP-A501 in Danon disease, a fatal lysosomal storage cardiomyopathy with no approved therapy. The thesis resolves on whether RP-A501's 12-month co-primary endpoints — myocardial LAMP2 expression and left ventricular mass reduction — demonstrate sufficient effect to support accelerated approval. The pivotal path relies on surrogate endpoints in a 12-patient study, creating meaningful approvability risk if FDA's post-marketing verification standard proves difficult to satisfy.